Murugaiyan , G. and Saha, S. (2013) IL-27 in tumor immunity and immunotherapy. Trends in Molecular Medicine , 19 (2). pp. 108-116.

Full text not available from this repository. (Request a copy)

Abstract

Inflammation has a central role in cancer progression. Metastatic tumors arise at sites of chronic inflammation, and tumors or tumor-infiltrating immune cells produce inflammatory mediators. By contrast, natural killer (NK) cells and cytotoxic T cells (CTLs) help eliminate premalignant lesions and limit the rate of tumor metastasis. Interleukin (IL)-27 is an IL-12 family cytokine chiefly produced by antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages, and alone or in combination with other cytokines, IL-27 boosts antitumor immunity by contributing to the development of NK cells and CTLs – a central immnunomodulatory effect – and by exerting potent antiangiogenic and antimetastatic activities, a local antitumor effect. In this review, we argue that by virtue of its rate-limiting functions in innate and adaptive immune responses, modulating IL-27 holds considerable promise for future cancer immunotherapy.

Item Type:	Article
Subjects:	Cancer Biology Infection and Immunity
Depositing User:	Mr. Rameshwar Nema
Date Deposited:	10 Apr 2015 04:31
Last Modified:	02 Jul 2015 10:12
URI:	http://nccs.sciencecentral.in/id/eprint/33

Actions (login required)

View Item